Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.

Saved in:
Bibliographic Details
Title: Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Authors: Marshall AD; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; Centre for Social Research in Health, University of New South Wales, Sydney, NSW, Australia. Electronic address: amarshall@kirby.unsw.edu.au., Willing AR; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Kairouz A; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Cunningham EB; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Wheeler A; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., O'Brien N; Macquarie University, Sydney, NSW, Australia., Perera V; Macquarie University, Sydney, NSW, Australia., Ward JW; Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, USA., Hiebert L; Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, USA., Degenhardt L; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia., Hajarizadeh B; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Colledge S; National Drug Research Institute, Curtin University, Perth, WA, Australia., Hickman M; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Jawad D; Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Lazarus JV; Barcelona Institute for Global Health (IS Global), Hospital Clinic, University of Barcelona, Barcelona, Spain; CUNY Graduate School of Public Health and Health Policy, New York, NY, USA., Matthews GV; Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; St Vincent's Hospital, Darlinghurst, Sydney, NSW, Australia., Scheibe A; TB HIV Care, Cape Town, South Africa; Community Orientated, Primary Care Research Unit, Department of Family Medicine, University of Pretoria, Pretoria, South Africa., Vickerman P; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Dore GJ; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Grebely J; Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Corporate Authors: Global HCV and HIV Treatment Restrictions Group
Source: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Apr; Vol. 9 (4), pp. 366-382. Date of Electronic Publication: 2024 Feb 15.
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2468-1253
DOI:10.1016/S2468-1253(23)00335-7